MetrioPharm Press Releases
-
Dr. Stephan Rietiker elected as new Chairman of the Board of MetrioPharm AG
MetrioPharm AG announced today that the new Board of Directors unanimously elected Dr. Stephan Rietiker as Chairman at its constituent meeting
-
Four new members elected to the Board of Directors of MetrioPharm AG
MetrioPharm AG announced today that four new members were elected to the Board of Directors at an Extraordinary General Meeting on April 17, 2025.
-
MetrioPharm Establishes Scientific Advisory Board of Seasoned Immunology and Pediatric Experts
MetrioPharm AG today announced that it has established a Scientific Advisory Board (SAB). The new advisors will supply expertise in immunology, pathology, inflammatory processes and in MetrioPharm's lead indication Duchenne muscular dystrophy.
-
MetrioPharm Publishes First Trial Data Showing Effects of Host-Directed Therapy in COVID-19
MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory and infectious diseases, announced today that results from its clinical trial CT-05 in hospitalised patients with moderate to severe COVID-19 have been published in the renowned journal The Lancet Regional Health – Europe.
-
MetrioPharm Receives Rare Pediatric Disease Designation (RPDD) for MP1032 from the U.S. FDA
MetrioPharm AG announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) for MP1032 for the treatment of Duchenne muscular dystrophy.
-
MetrioPharm Receives Orphan Drug Designation for the Treatment of Duchenne Muscular Dystrophy
FDA grants orphan drug designation for MetrioPharm's lead compound MP1032 for the treatment of Duchenne muscular dystrophy (DMD).
-
MetrioPharm Announces Topline Data of its Phase IIa Study of MP1032 in COVID-19 Patients
MP1032 has many advantages over other available antivirals: it can be conveniently administered orally and has both anti-inflammatory and anti-Sars-CoV-2 properties, making it an ideal candidate to prevent a so-called cytokine storm.
-
MetrioPharm Starts Preclinical Experiments in Duchenne Muscular Dystrophy (DMD)
DMD is classified as an orphan (rare) disease of high unmet medical need. New treatments for orphan diseases receive priority support during development and market authorization from the EMA and the US FDA.
-
Last Patient Out: MetrioPharm Completes Clinical Phase II Trial in COVID-19
The objective of the study is to determine whether treatment with MetrioPharm’s lead compound MP1032 can slow the spread of the virus and alleviate COVID-19 symptoms in recently hospitalized patients.In preclinical trials the compound had shown both antiviral and anti-inflammatory properties.
-
MetrioPharm surpasses 50% of enrollment in Phase II study in COVID-19
The objective of the study is to determine whether the anti-inflammatory effect of MP1032 can slow the spread of the virus in recently hospitalized patients with moderate to severe coronavirus disease and alleviate COVID-19 symptoms.